News & Updates
Excerpt from the Press Release: REDWOOD CITY, Calif.–(BUSINESS WIRE)–Meissa Vaccines (“Meissa”), a biotechnology company developing vaccines to prevent serious viral respiratory infections, announced today the release of preclinical data in nonhuman primates (NHPs) of the company’s intranasal recombinant live attenuated COVID-19 vaccine (MV-014-212). The data demonstrate that a single adjuvant-free dose of MV-014-212 provided equivalent protection against SARS-CoV-2…Read More
Excerpt from the Press Release: SAN FRANCISCO, CA / ACCESSWIRE / July 20, 2021 / Oncology Pharma Inc. (OTC PINK:ONPH) Oncology Pharma, Inc. (the “Company”) is laying out and taking necessary steps to move its licensed IP forward. From obtaining the necessary financing, in order to support studies, to obtaining the data utilizing mouse or rat…Read More
Excerpt from the Press Release: SPRINGFIELD, Mo. & REDWOOD CITY, Calif.–(BUSINESS WIRE)–Fight Colorectal Cancer (Fight CRC), the nation’s leading colorectal cancer (CRC) patient advocacy organization, and Guardant Health, Inc. (Nasdaq: GH), a leader in precision oncology, will be recognizing clinical researchers and advocates who have demonstrated exceptional leadership during the pandemic in getting people back…Read More
Excerpt from the Press Release: CAMBRIDGE, Mass., July 20, 2021 (GLOBE NEWSWIRE) — Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, today announced that multiple participants have initiated dosing in the Phase 1b/2a FOCUS-C9 clinical trial evaluating WVE-004 as an investigational treatment…Read More
Excerpt from the Press Release: WATERTOWN, Mass.–(BUSINESS WIRE)–Lyndra Therapeutics, a clinical-stage biotechnology company working to make daily pills a thing of the past, today announced the positive outcome of an end-of-phase 2 (EOP2) meeting with the U.S. Food and Drug Administration (FDA) providing a clear path to approval for Lyndra’s Weekly Risperidone (LYN-005), the company’s…Read More
Excerpt from the Press Release: MONMOUTH JUNCTION, N.J., July 19, 2021 (GLOBE NEWSWIRE) — Elucida Oncology, a biotechnology company pioneering the next frontier in targeted cancer therapy, announced today that it has submitted an Investigational New Drug Application (IND) to the U.S. Food and Drug Administration (FDA) for a Phase 1/2 clinical trial of ELU-001,…Read More
Excerpt from the Press Release: LAWRENCEVILLE, N.J., July 19, 2021 (GLOBE NEWSWIRE) — Celsion Corporation (NASDAQ: CLSN), a clinical-stage company focused on DNA-based immunotherapy and next-generation vaccines, today announced that following a pre-planned interim safety review of 55 as treated patients randomized in the Phase I/II OVATION 2 Study with GEN-1 in advanced (Stage III/IV) ovarian cancer, the Data…Read More
Excerpt from the Press Release: SAN DIEGO–(BUSINESS WIRE)–Selva Therapeutics, Inc. (“Selva”) announced new preclinical data demonstrating SLV213, when given as a prophylactic or a treatment for SARS-CoV-2 infection, protects against SARS-CoV-2-induced diffuse alveolar damage (DAD), which is associated with the early stages of acute respiratory distress syndrome (ARDS). Additional in vitro data show that SLV213 greatly enhances the…Read More
Excerpt from the Press Release: SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Tenaya Therapeutics, a biotechnology company with a mission to discover, develop and deliver curative therapies that address the underlying causes of heart disease, has unveiled preclinical data supporting drug discovery efforts involving its Precision Medicine Platform at the European Society of Cardiology Heart Failure 2021 (ESC-HF) meeting. The…Read More
Excerpt from the Press Release: Cambridge, MA, July 12, 2021 (GLOBE NEWSWIRE) — Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit” or the “Company”) is today displaying three preeminent ePosters at the prestigious 31st European Congress of Clinical Microbiology & Infectious Diseases (ECCMID). Two ePosters bring increased awareness and understanding of the significance of data generated using…Read More
Request Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?